


or a pharmaceutically acceptable salt thereof

Figure 1A


206220" / SET 500T




or a pharmaceutically acceptable salt thereof

Figure 1B

2006270799T500T



I



II

Figure 1C

206270-29ET500F





Figure 1D

20054367.072003




I

or a pharmaceutically acceptable salt thereof
 R_1 and R_3 are the same and are:

Figure 1E

20627079ET500F




I

or pharmaceutically acceptable salt thereof

2006270795001

Figure 1F



I

or

II,

or pharmaceutically acceptable salt thereof,

Figure 1G











Figure 1H



10113
MnTE-2-PyP




10123
MnTDM-2,5-IP



10143


Figure 1H (continued)






10150


MnTDE-2,5-IP



10151




10153



10158

MnTDP-2,5-IP



10201

MnTBAP

Figure 1H (continued)

Figure 2A

B16 Melanoma tumor - SOD mimetic treatment




Figure 2B




Figure 2C

Effect of Radiation & A EOL 10113 on Mammary Adenocarcinoma




Figure 3

Tumor Growth Inhibition
R3230 AC Mammary Adenocarcinoma in Fisher rats




Figure 4

Tumor growth inhibition (s.q. chambers)

Dose = 6 mg/kg








Figure 5

Tumor Angiogenesis
Dose = 6 mg/kg



206220 " 072902 10051367 "



Catalytic Antioxidant Metalloporphyrin
[MnTBAP]

Figure 6

Figure 7




Figure 8




Figure 9A





Figure 9B



206270" / 9ET500T

JUL 29 2002
PATENT & TRADE




Figure 10A



Figure 10E




Figure 10B




Figure 10F



Figure 10C



Figure 10G




Figure 10D



Figure 10H

Figure 11




Figure 12




Figure 13A




Figure 13B




Figure 14




Figure 15





Figure 16

A549 3H-Thymidine uptake at 24 hours



206220" 29ET500T



Figure 17A

Paraquat-Induced Injury of Human A549 Cells (48 hr)





Figure 17B

Effect of MnTBAP on Paraquat-Induced A549 Cell Injury



206240" 498T500T



Figure 17C

Effect of ZnTBAP on
Paraquat-Induced A549 Cell Injury




Figure 17D

Effect of MnTMPyP on
Paraquat-Induced A549 Cell Injury







Figure 17E

Effect of ZnTMPyP on
Paraquat-Induced A549 Cell Injury



INC-01 Blinded Mucositis Scores




Figure 18



Figure 19
Percentage of Study Days with Ulceration as
Indicated by a Score of 3 or Greater

